Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the bodyâs remarkable capacity for cellular growth and repair. Our approach to drug discovery is driven by deep scientific expertiseâand an urgency to deliver effective treatments to thousands of patients who have few or no therapeutic options. The Companyâs lead product candidate, luspatercept, is a first-in-class erythroid (red blood cell) maturation agent (EMA) being developed to treat patients who have serious blood disorders marked by a late-stage defect in the maturation of red blood cells. Alongside our partner Celgeneâa leader in hematologyâwe are advancing multiple Phase 2 and Phase 3 trials of luspatercept in five target indications across myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing a neuromuscular program with a locally-acting âMyostatin+â agent, ACE-083. We recently initiated a Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH). Acceleron has ongoing preclinical research efforts targeting additional indications in these three disease areas in which there is high unmet medical need. Source
No articles found.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
The DNA ID platform is a community marketplace for genomics research. The app allo...
The DNA ID platform is a community marketplace ...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Join the National Investor Network and get the latest information with your interests in mind.